Topotarget A/S Copen (TPTGF) 0.6806 $TPTGF
Therapeutic Report for Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
M2 - Tue Aug 06, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sqnpw/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the acute lymphocytic leukemia therapeutic pipeline. It provides information on the therapeutic development for acute lymphocytic leukemia complete with latest updates, and special features on late-stage and discontinued projects. The document is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for acute lymphocytic leukemia. - A review of the acute lymphocytic leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the acute lymphocytic leukemia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for acute lymphocytic leukemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding acute lymphocytic leukemia pipeline depth and focus of acute lymphocytic leukemia therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Acute Lymphocytic Leukemia Overview Therapeutics Development An Overview of Pipeline Products for Acute Lymphocytic Leukemia Companies Involved in Acute Lymphocytic Leukemia Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned (40) Including: - 4SC AG - Ariad Pharmaceuticals - Bio-Path Holdings - Bristol-Myers Squibb Company - CanBas Co - Exelixis - F. Hoffmann-La Roche - Genzyme Corporation - Hana Biosciences - Incyte Corporation - Jazz Pharmaceuticals - KaloBios Pharmaceuticals - Lentigen Corporation - Millennium Pharmaceuticals - MorphoSys AG - Mundipharma International - Novartis AG - Onconova Therapeutics - Oryzon - Pfizer - Proacta - Sigma-Tau Pharmaceuticals - SuperGen - SymbioTec GmbH - Threshold Pharmaceuticals - TopoTarget A/S - Tragara Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/5s...ymphocytic
T-Cell Lymphomas - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pz4gz2/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for T-Cell lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell lymphomas. The document is built using data and information proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for T-Cell lymphomas. - A review of the T-Cell lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the T-Cell lymphomas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for T-Cell lymphomas. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding T-Cell lymphomas pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage T-Cell Lymphomas Overview Therapeutics Development An Overview of Pipeline Products for T-Cell Lymphomas Companies Involved in T-Cell Lymphomas Therapeutics Development T-Cell Lymphomas - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Abbott Laboratories - Allos Therapeutics, Inc - Amgen Inc - Celgene Corporation - Cephalon - Chipscreen Biosciences Ltd - Eisai Co - Emergent BioSolutions Inc - Incyte Corporation - Kyowa Hakko Kirin Co - Millennium Pharmaceuticals - Mundipharma International Limited - Nerviano Medical Sciences - PharmaMar - Pharmacyclics, Inc - Sareum Holdings - Seattle Genetics, Inc - TopoTarget A/S - Xencor, Inc - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/pz..._lymphomas
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:22AM CDT
Research and Markets has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013" report to their offering. 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL). Scope - A snapshot of the global therapeutic scenario for Peripheral T-Cell Lymphomas (PTCL). - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects o
Soft Tissue Sarcoma - Pipeline Review, H2 2012
M2 - Mon Jan 07, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/f4g9mh/soft_tissue) has announced the addition of Global Markets Direct's new report "Soft Tissue Sarcoma - Pipeline Review, H2 2012" to their offering. 'Soft Tissue Sarcoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Soft Tissue Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma. Soft Tissue Sarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important and di
Therapeutic Report for Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
M2 - Tue Aug 06, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sqnpw/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the acute lymphocytic leukemia therapeutic pipeline. It provides information on the therapeutic development for acute lymphocytic leukemia complete with latest updates, and special features on late-stage and discontinued projects. The document is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for acute lymphocytic leukemia. - A review of the acute lymphocytic leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the acute lymphocytic leukemia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for acute lymphocytic leukemia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding acute lymphocytic leukemia pipeline depth and focus of acute lymphocytic leukemia therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Acute Lymphocytic Leukemia Overview Therapeutics Development An Overview of Pipeline Products for Acute Lymphocytic Leukemia Companies Involved in Acute Lymphocytic Leukemia Therapeutics Development Drug Profiles Featured News & Press Releases Appendix Companies Mentioned (40) Including: - 4SC AG - Ariad Pharmaceuticals - Bio-Path Holdings - Bristol-Myers Squibb Company - CanBas Co - Exelixis - F. Hoffmann-La Roche - Genzyme Corporation - Hana Biosciences - Incyte Corporation - Jazz Pharmaceuticals - KaloBios Pharmaceuticals - Lentigen Corporation - Millennium Pharmaceuticals - MorphoSys AG - Mundipharma International - Novartis AG - Onconova Therapeutics - Oryzon - Pfizer - Proacta - Sigma-Tau Pharmaceuticals - SuperGen - SymbioTec GmbH - Threshold Pharmaceuticals - TopoTarget A/S - Tragara Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/5s...ymphocytic
T-Cell Lymphomas - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pz4gz2/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for T-Cell lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell lymphomas. The document is built using data and information proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for T-Cell lymphomas. - A review of the T-Cell lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the T-Cell lymphomas pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for T-Cell lymphomas. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding T-Cell lymphomas pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage T-Cell Lymphomas Overview Therapeutics Development An Overview of Pipeline Products for T-Cell Lymphomas Companies Involved in T-Cell Lymphomas Therapeutics Development T-Cell Lymphomas - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Abbott Laboratories - Allos Therapeutics, Inc - Amgen Inc - Celgene Corporation - Cephalon - Chipscreen Biosciences Ltd - Eisai Co - Emergent BioSolutions Inc - Incyte Corporation - Kyowa Hakko Kirin Co - Millennium Pharmaceuticals - Mundipharma International Limited - Nerviano Medical Sciences - PharmaMar - Pharmacyclics, Inc - Sareum Holdings - Seattle Genetics, Inc - TopoTarget A/S - Xencor, Inc - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/pz..._lymphomas
Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:22AM CDT
Research and Markets has announced the addition of the "Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013" report to their offering. 'Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL). Scope - A snapshot of the global therapeutic scenario for Peripheral T-Cell Lymphomas (PTCL). - A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects o
Soft Tissue Sarcoma - Pipeline Review, H2 2012
M2 - Mon Jan 07, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/f4g9mh/soft_tissue) has announced the addition of Global Markets Direct's new report "Soft Tissue Sarcoma - Pipeline Review, H2 2012" to their offering. 'Soft Tissue Sarcoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Soft Tissue Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma. Soft Tissue Sarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Reasons to buy - Identify and understand important and di
